Results 11 to 20 of about 761 (100)

Etrasimod in Treatment of Ulcerative Colitis: A Comprehensive Review [PDF]

The Turkish Journal of Gastroenterology
Ulcerative colitis (UC) is a chronic, inflammatory disease of the colon. The unpredictable, systemic, and debilitating nature of UC puts disease management and patient monitoring at a pivotal point.
Osman Cagin Buldukoglu, Yusuf Erzin, Ayhan Hilmi Cekin, Silvio Danese   +3 more
doaj   +3 more sources

Unique pharmacological properties of etrasimod among S1P receptor modulators

FEBS Open Bio
Etrasimod (ADP334) is an oral, once‐daily, selective sphingosine 1‐phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis and in development for the treatment of immune‐mediated inflammatory diseases.
John W Adams
exaly   +3 more sources

Model-Based Dose Selection of a Sphingosine-1-Phosphate Modulator, Etrasimod, in Patients with Various Degrees of Hepatic Impairment

Pharmaceutics
Background/Objectives: Etrasimod is a newly FDA-approved Sphingosine-1-Phosphate modulator indicated for moderate and severe ulcerative colitis. It is extensively metabolized in the liver via the cytochrome P450 system and may accumulate markedly in ...
Abdullah Alsultan, Fawaz Alasmari, Faleh Alqahtani   +2 more
exaly   +4 more sources

Etrasimod: Modulating Sphingosine-1-Phosphate Receptors to Treat Ulcerative Colitis [PDF]

Journal of Clinical Medicine
This review aimed to provide a comprehensive overview of the current landscape of etrasimod. Etrasimod is an oral, once-daily selective modulator of sphingosine 1-phosphate receptors (S1PR), developed for the treatment of moderately to severely active ...
Begoña Gonzalez Suarez, Cristina Martínez-Molina   +1 more
exaly   +3 more sources

Repurposing the Sphingosine-1-Phosphate Receptor Modulator Etrasimod as an Antibacterial Agent Against Gram-Positive Bacteria [PDF]

Frontiers in Microbiology, 2022
New classes of antibiotics are urgently needed in the fight against multidrug-resistant bacteria. Drug repurposing has emerged as an alternative approach to accelerate antimicrobial research and development.
Matej Zore, Shella Gilbert-Girard, Paola San-Martin-Galindo, Inés Reigada, Leena Hanski, Kirsi Savijoki, Adyary Fallarero, Jari Yli-Kauhaluoma, Jayendra Z. Patel   +8 more
doaj   +2 more sources

Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program [PDF]

Inflammatory Bowel Diseases
BACKGROUND: Etrasimod is an oral, once daily (QD), selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC).
Aoibhinn McDonnell, Michael Chiorean
exaly   +3 more sources

S1PR4-dependent effects of Etrasimod on primary human myeloid immune cell activation [PDF]

Frontiers in Pharmacology
BackgroundSphingosine-1-phosphate (S1P) and its five receptors S1PR1-5 play an essential role in the migration, differentiation and activation of various immune cells.
Fiona K. Sailer, Megan A. Palmer, Blerina Aliraj, Jan Heering, Jan Heering, Andreas Brockmann, Mohammed A. F. Elewa, Mohammed A. F. Elewa, Aissa Röhrig, Aissa Röhrig, Ewgenij Proschak, Ewgenij Proschak, Ewgenij Proschak, Dariusz T. Stepniak, Simeon Ramsey, Bernhard Brüne, Bernhard Brüne, Andreas Weigert   +17 more
doaj   +2 more sources

Sphingosine-1-Phosphate (S1P) Receptor Modulators for the Treatment of Inflammatory Bowel Disease (IBD): Mechanisms, Clinical Evidence, and Practical Insights [PDF]

Biomedicines
Inflammatory bowel disease commonly requires advanced therapies to induce and maintain durable remission. Sphingosine-1-phosphate receptor modulators are the latest class of orally administered small molecules that have been added to the therapeutic ...
Natalie Shields, Michael Colwill, Valentina Raspa, Yaw Twum-Danso, Andrew Poullis, Kamal Patel, Sailish Honap   +6 more
doaj   +2 more sources

Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: an analysis of the phase II OASIS and phase III ELEVATE UC 52 and ELEVATE UC 12 clinical trials

Therapeutic Advances in Gastroenterology
Background: Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate (S1P) 1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). It is known that non-serious treatment-emergent adverse events
Charlie W. Lees, Joana Torres, Yvette Leung, Séverine Vermeire, Marc Fellmann, Irene Modesto, Aoibhinn McDonnell, Krisztina Lazin, Michael Keating, Martina Goetsch, Joseph Wu, Edward V. Loftus   +11 more
doaj   +2 more sources

Development and optimization of etrasimod-loaded pH-dependent nanoparticles for colon targeted drug delivery [PDF]

Journal of Applied Pharmaceutical Research
Background: Etrasimod-loaded pH-sensitive nanoparticles offer a promising strategy for targeted drug delivery to the colon, minimizing systemic exposure and enhancing therapeutic efficacy.
Rahul Godge, Tejas Sahane, Shubham Mhaske, Sneha Vikhe, Santosh Dighe   +4 more
doaj   +2 more sources